Depyrogenated Sterile Empty Vials Market To Generate Revenue Worth $4,521.7 Million by 2030

The global depyrogenated sterile empty vials market is projected to generate USD 4,521.7 million revenue by 2030, advancing at a CAGR of 4.9% during 2022–2030. This can be ascribed to the rising number of clinical laboratories, technological developments in pharmaceutical packaging, and rapid expansion of the pharmaceutical industry.

The depyrogenation method is an important part of the development of packaging solutions for injectable medicine. Pharmaceutical packaging components, including ampoules and vials, require detailed depyrogenation procedures on the basis of the materials of the components. The commonly used techniques are ultrafiltration, moist heat, dry heat, and rinsing.

Compounding Labs Held a Significant Share

The compounding labs category held a revenue share of 20% in 2022. This is mainly because these labs specialize in creating customized medications tailored to meet the unique needs of individual patients. They can adjust medication strengths, dosage forms, and flavors, and combine multiple medications into a single formulation. This customization is particularly beneficial for patients who have specific allergies, sensitivities, or difficulty with commercially available medication.

Also, compounding labs can prepare medications in specific dosages that are not commercially available. This is especially important for patients who require personalized dosing based on factors such as age, weight, or medical conditions. Compounded medications allow healthcare providers to precisely adjust the dosage to optimize therapeutic outcomes. Moreover, these labs offer a variety of alternative delivery methods beyond standard oral tablets or capsules. They can also help create creams and gels, which are useful for specific patients.

Globally, Europe accounts for a significant share of the market. This is mainly because of the growing pharmaceutical sector across various countries in the region. With the formation of biological medications, the sector’s landscape has undergone major changes.

In Europe, Germany is the largest manufacturer of EU-approved active biopharmaceutical ingredients, where more than half of active biopharmaceutical substances are manufactured in South Germany. This area has over 100 research, pharmaceutical, biotechnological, and medical technology firms. In addition, Germany promotes cutting-edge technology for both drug development and biopharmaceutical producers. The country also provides an ideal environment for the creation and manufacture of high-quality products that need extensive study.

Additionally, the demand for depyrogenated sterile empty vials is increasing in the region, due to the rising instances of infectious diseases. For instance, in 2020, in the U.K., there were around 0.2 million HIV cases, i.e., 2 in every 1,000 people.

Moreover, in France, the geriatric population has grown rapidly, and they are more vulnerable to many infectious and non-infectious diseases and require urgent medical attention. This is mainly because of the sedentary lifestyle and unhealthy habits of eating. Thus, due to the increasing cases of infectious diseases, various tests are done in clinical labs for understanding the cause, which, in turn, increases the use of these vials.

Furthermore, in LATAM, the market is expected to expand rapidly in the coming years. This can be because the population in the region is becoming prone to older age-related illnesses and chronic diseases, the surging income in some demographic segments driving a desire for quality healthcare services, the rising healthcare spending by governments, and multinational and local companies are investing heavily to expand their footprint in the region.

Major players operating in the depyrogenated sterile empty vials market include Thermo Fisher Scientific Inc., VWR International LLC, Corning Incorporated, APG Pharma, DWK Life Sciences, Gerresheimer AG, Stevanato Group, SGD Pharma, and SCHOTT AG.